CEA, iBiTec-S, Service d'Ingénierie Moléculaire des Protéines-SIMOPRO, Gif-sur-Yvette F-91191, France.
J Struct Biol. 2013 Jun;182(3):246-54. doi: 10.1016/j.jsb.2013.03.015. Epub 2013 Apr 6.
Homodimerization is important in signal transduction and can play a crucial role in many other biological systems. To obtaining structural information for the design of molecules able to control the signalization pathways, the proteins involved will have to be crystallized in complex with ligands that induce dimerization. Bi-functional drugs have been generated by linking two ligands together chemically and the relative crystallizability of complexes with mono-functional and bi-functional ligands has been evaluated. There are problems associated with crystallization with such ligands, but overall, the advantages appear to be greater than the drawbacks. The study involves two matrix metalloproteinases, MMP-12 and MMP-9. Using flexible and rigid linkers we show that it is possible to control the crystal packing and that by changing the ligand-enzyme stoichiometric ratio, one can toggle between having one bi-functional ligand binding to two enzymes and having the same ligand bound to each enzyme. The nature of linker and its point of attachment on the ligand can be varied to aid crystallization, and such variations can also provide valuable structural information about the interactions made by the linker with the protein. We report here the crystallization and structure determination of seven ligand-dimerized complexes. These results suggest that the use of bi-functional drugs can be extended beyond the realm of protein dimerization to include all drug design projects.
同源二聚化在信号转导中很重要,在许多其他生物系统中也起着至关重要的作用。为了获得能够控制信号通路的分子设计的结构信息,必须将涉及的蛋白质与诱导二聚化的配体复合后进行结晶。通过将两个配体化学连接,已经产生了双功能药物,并且已经评估了具有单功能和双功能配体的复合物的相对结晶能力。与这种配体进行结晶存在问题,但总体而言,其优点似乎大于缺点。本研究涉及两种基质金属蛋白酶,MMP-12 和 MMP-9。我们使用柔性和刚性接头表明,有可能控制晶体堆积,并且通过改变配体-酶的化学计量比,可以在一个双功能配体结合两个酶和相同的配体结合每个酶之间进行切换。接头的性质及其在配体上的连接点可以改变以促进结晶,并且这种变化还可以提供有关接头与蛋白质相互作用的有价值的结构信息。我们在这里报告了七种配体二聚化复合物的结晶和结构测定。这些结果表明,双功能药物的使用可以扩展到蛋白质二聚化之外,包括所有药物设计项目。